Skip to content

Interactions Between Diet, Microbiome and Abiotic Conditions in the Gut

Towards Personalized Dietary Recommendations Based on the Interaction Between Diet, Microbiome and Abiotic Conditions in the Gut

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04804319
Acronym
PRIMA
Enrollment
63
Registered
2021-03-18
Start date
2021-04-13
Completion date
2021-11-29
Last updated
2024-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diet, Healthy, Metabolic Disease

Keywords

Microbiome, Metabolomics, Nutrition

Brief summary

The aim of this study is to explore the interplay between environmental (abiotic) factors in the gut and the gut microbiota composition, diversity and metabolism. Such insights could help us understand personal responses to diets and be a first step towards personalized dietary recommendations targeting the gut microbiome.

Detailed description

The study is a 9-day trial including 85 healthy adults in age between 18 and 75. The participants will throughout the trial register their dietary intake, gastrointestinal symptoms including stool frequency and Bristol stool scale, physical activity, and medicine and supplements intake. Participants will on day 3 and day 5, respectively, consume sweet corns to estimate intestinal transit time by the time it takes sweet corn to travel through the gastrointestinal system. Furthermore, the participants will collect daily urine and stool samples. On day 2 and day 9, participants will arrive fasting at the department in the morning and have their anthropometry, breath hydrogen and methane levels measured, and a blood sample will be collected from each participant. The first visit (day 2) also includes a standardized meal test (rye bread, butter, jam, egg, and yogurt with nuts and berries) and intake of paracetamol (250 mg). Subsequently, the participants will stay at the department for the following 6 hours and have their postprandial breath hydrogen and methane measured and urine collected at specific intervals. Moreover, a sub-set of the participants will on the first visit (day 2) immediately after intake of the standardized meal swallow a single-use gastrointestinal SmartPill capsule, which will monitor their gastrointestinal pH, transit time, temperature and pressure.

Interventions

OTHER9-days habitual diet

9-days study with habitual diet including one standardized breakfast on a single day

Sponsors

Technical University of Denmark
CollaboratorOTHER
KU Leuven
CollaboratorOTHER
University of Minnesota
CollaboratorOTHER
University of Copenhagen
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* 18.5-30.0 kg/m2 BMI * Willing to daily collect a urine and stool sample at home and able to store them in their own freezer in a provided containers throughout the 9-days trial * Willing to eat sweet corn and report corn-intestinal transit time questionnaire * Willing to record 9 days dietary intake and defecation pattern * Willing to have blood samples drawn two times * Owns a device with access to the internet and is willing to use myfood24 platform * Known ability to tolerate paracetamol and willing to consume ½ paracetamol tablet dissolved in water (250mg) * Willing to eat rye bread, butter, jam, egg, yoghurt, berries and nuts

Exclusion criteria

* Any condition that makes the project responsible researcher to doubt the feasibility of the volunteer´s participation * Pregnant or lactating women * Suffering from inflammatory bowel syndrome (IBS), small intestinal bacterial overgrowth (SIBO) or inflammatory bowel diseases (IBD) * Intake of antibiotics, diarrhea inhibitors and laxatives ˂ 1month * Current chronic or infectious diseases * Diagnosis of diabetes * History of cancer within the past 5 years (except adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer) * Frequent intake of painkillers or other medication (mild antidepressants and contraceptive pills are allowed) * Concurrent participation in another trial Additional

Design outcomes

Primary

MeasureTime frameDescription
Faecal pH vs gut microbial saccharolytic/proteolytic metabolismDay 1-9We test whether faecal pH is positively associated with microbial-derived proteolytic metabolites (i.e. p-cresol sulfate and phenylacetylglutamine) in urine and negatively associated with microbial-derived saccharolytic metabolites in faeces (i.e. acetate, butyrate and propionate)

Secondary

MeasureTime frameDescription
Abiotic factors vs faecal metabolomeDay 1-9We test whether day-to-day variations in abiotic factors (faecal and/or intestinal pH, faecal redox potential, intestinal transit time and substrate availability) are associated with changes in the faecal metabolome
Abiotic factors vs urine metabolomeDay 1-9We test whether day-to-day variations in abiotic factors (faecal and/or intestinal pH, faecal redox potential, intestinal transit time and substrate availability) are associated with changes in the urine metabolome
Abiotic factors vs faecal metagenomic profileDay 1-9We test whether day-to-day variations in abiotic factors (faecal and/or intestinal pH, faecal redox potential, intestinal transit time and substrate availability) are associated with changes in the faecal microbiome
Abiotic factors vs microbial-derived metabolitesDay 1-9We test whether day-to-day variations in abiotic factors (faecal and/or intestinal pH, faecal redox potential, intestinal transit time and substrate availability) are associated with changes in diet-derived microbial metabolites in blood/urine/faeces, including short-chain fatty acids, secondary bile acids, phenolic and indolic compounds, branched-chain fatty acids, trimethylamine N-oxide, hippuric acid, urolithin, and enterolactone
Faecal metagenomics profile vs metabolomeDay 1-9We test whether day-to-day variations in the microbiome are associated with changes in diet-derived microbial metabolites in blood/urine/faeces, including short-chain fatty acids, secondary bile acids, phenolic and indolic compounds, branched-chain fatty acids, trimethylamine N-oxide, hippuric acid, urolithin, and enterolactone
Abiotic factors vs blood metabolomeDay 2 and 9We test whether day-to-day variations in abiotic factors (faecal and/or intestinal pH, faecal redox potential, intestinal transit time and substrate availability) are associated with changes in the blood (serum) metabolome

Other

MeasureTime frameDescription
Blood metabolomeDay 2 and 9Changes in the blood metabolome within and between volunteers as determined by untargeted metabolic profiling by LC-MS of fasting blood samples collected at day 2 and day 9
Fasting breath hydrogen and methaneDay 2 and 9Measurement of fasting breath hydrogen and methane exhalation at day 2 and day 9
Postprandial breath hydrogen and methaneDay 2Measurement of fasting and postprandial breath hydrogen and methane exhalation after standardized breakfast (every 30 min until 6 hours post-meal)
Faecal levels of short chain fatty acidsDay 1-9Measurements of short-chain fatty acids in all faecal samples collected from day 1 to day 9 determined by LC-MS
Intestinal transit timeDay 2-71. Whole transit time variation within and between volunteers as determined by the sweet-corn test. Briefly, participants are instructed to consume sweet corns twice, on day 3 and 5, and to record the times until visible corn excretion on these two occasions, as well as their defecation frequency, and stool consistency during days 1 to 9 2. Whole transit time variation within and between volunteers as determined by the SmartPill Wireless Motility Capsule in the subgroup 3. Comparison of the whole intestinal transit time data obtained by the Smartpill Wireless Motility Capsule and results from the sweet-corn test in the subgroup 4. Small bowel transit time determined by the SmartPill Wireless Motility Capsule in the subgroup 5. Colonic transit time determined by the SmartPill Wireless Motility Capsule in the subgroup
Gastric emptyingDay 21. Fluid gastric emptying time determined by the presence of paracetamol metabolites in postprandial urine samples 2. Solid gastric emptying time determined by the SmartPill Wireless Motility Capsule in the subgroup
Appetite hormonesDay 2 and 9Determination of different appetite hormones in fasting blood samples at day 2 and day 9 to record baseline values
Glucose levelsDay 2 and 9Measurements of glucose in fasting blood samples at day 2 and day 9
Insulin levelsDay 2 and day 9Measurement of insulin levels in fasting blood samples at day 2 and day 9
C-peptide levelsDay 2 and day 9Measurement of C-peptide levels in fasting blood samples at day 2 and day 9
HbA1c levelsDay 2 and day 9Measurement of HbA1c levels in fasting blood samples at day 2 and day 9
Immune system markersDay 2 and 9Measurements of fasting plasma cytokines, C-reactive protein (CRP), lipopolysaccharides (LPS), lipopolysaccharide binding protein (LPS-BP) at day 2 and day 9 to record baseline values
Lipid metabolismDay 1-9Determination of bile acids in fasting blood samples at day 2 and day 9 and in all faecal samples from day 1 to day 9 to associate with changes in abiotic factors
9-days dietary intakeDay 1-9Assessment of dietary intake via myfood24 dietary recalls from day 1 to day 9
Faecal nitrogenDay 1-9Assessment of nitrogen in all faecal samples from day 1 to day 9
Faecal residual carbohydratesDay 1-9Assessment of residual carbohydrates in all faecal samples from day 1 to day 9
Faecal energyDay 1-9Assessment of total energy in all faecal samples from day 1 to day 9
Microbial load assessed by qPCRDay 1-9Assessment of microbial load by quantitative PCR in all faecal samples from day 1 to day 9
Plasma levels of short chain fatty acidsDay 2 and day 9Measurement of fasting plasma short-chain fatty acids determined by LC-MS from day 2 and day 9
Faecal pHDay 1-9Measurements of pH in all faecal samples from day 1 to day 9
Faecal redox potentialDay 1-9Measurements of redox potential in all faecal samples from day 1 to day 9
Faecal ionic strengthDay 1-9Measurements of ionic strength (Na+ and K+) in all faecal samples from day 1 to day 9
Faecal water contentDay 1-9Measurements of water content in all faecal samples from day 1 to day 9
Subjective gastrointestinal symptomsDay 1-9Gastrointestinal symptoms reported on a scale from 0 to 10, where 0 means no symptoms and 10 means the worst possible symptoms. The questionnaire includes these symptoms: overall stomach and intestine symptoms, stomachache, flatulence, bloating, constipation, and diarrhea.
CreatinineDay 2Measurements of urinary levels of creatinine from controlled 6-hour urine collection
Intestinal pHDay 2-7pH measurements throughout the gastrointestinal system determined by the SmartPill Wireless Motility Capsule in the subgroup
Intestinal epithelial cell sheddingDay 1-9Measurements of host DNA content in all faecal samples from day 1 to day 9
Microbial load assessed by flow cytometryDay 1-9Assessment of microbial cell counts by flow cytometry in all faecal samples from day 1 to day 9
Faecal microbiomeDay 1-9Determination of the variation in the intra- and inter-individual microbiomes in all faecal samples collected from day 1 to day 9
Faecal metabolomeDay 1-9Changes in the faecal metabolome within and between volunteers as determined by untargeted metabolic profiling by liquid chromatography mass spectrometry (LC-MS) of all faecal samples collected from day 1 to day 9
In vitro metabolic profilingDay 1-9Metabolic profiling of in vitro microbial communities inoculated by faecal outputs from the study
Urine metabolomeDay 1-9Changes in the urine metabolome within and between volunteers as determined by untargeted metabolic profiling by LC-MS of all urine samples collected from day 1 to day 9
Postprandial urine metabolomeDay 2Diet- and microbial-derived metabolites from the standardised meal determined by metabolic profiling by LC-MS of postprandial urine samples collected at 30 min, 1 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 6-8 hours, 8-10 hours, 10-24 hours
Food intake markersDay 2-3 and day 8-9Food intake biomarkers determined by metabolic profiling by LC-MS of 24-hour urine collection at day 2-3 and day 8-9.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026